Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed this Form 8-K on May 20, 2026, regarding its listing status on the Nasdaq Global Select Market. The filing addresses a prior notice of non-compliance with Nasdaq Listing Rule 5450(b)(2)(A) concerning the minimum market value of listed securities.
Key Financial Metrics
The filing references the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, to demonstrate compliance with Nasdaq Listing Rule 5450(b)(1)(A).
- Stockholders' Equity: $15,672,000 (as of March 31, 2026).
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The Company previously failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. However, based on the reported stockholders' equity of $15,672,000, the Company has regained compliance with Nasdaq's continued listing requirements. The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The primary risk addressed was the potential delisting due to market value requirements, which has been resolved.
Investor Verification Checklist
- Verify the current stock price and market capitalization to ensure continued compliance with Nasdaq listing rules.
- Review the full Form 10-Q for the quarter ended March 31, 2026, for detailed financial statements and cash flow analysis.
- Confirm the Company's ongoing operational status and pipeline progress as a biotechnology firm.